Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
30 août 2023 01h33 HE
|
Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
Zealand Pharma Announces Financial Results for the First Half of 2023
17 août 2023 01h00 HE
|
Zealand Pharma
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
30 juin 2023 13h32 HE
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
12 avr. 2023 11h00 HE
|
Zealand Pharma
Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq...
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
19 sept. 2022 02h00 HE
|
Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...
Crinetics Presents Clinical and Research Results at ENDO 2022
08 juin 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
30 mars 2022 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
15 sept. 2021 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in...
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
22 mars 2021 07h10 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
12 mars 2021 07h10 HE
|
Crinetics Pharmaceuticals, Inc.
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease...